FDA 483 - Baxter Oncology GmbH - November 05, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Baxter Oncology GmbH in Halle (Westf.), Germany, revealed significant deficiencies across multiple areas of drug product manufacturing. Key issues included failures in aseptic processing procedures, inadequate quality control oversight, and insufficient validation of cleaning processes, visual inspection, and critical utilities. The firm also demonstrated a lack of established accuracy for test methods and inadequate protection for electronic data acquisition systems.
ID · f8379713-5f2d-4c65-9d44-6d8d24e6bc75